<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187654</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Heart-002</org_study_id>
    <nct_id>NCT01187654</nct_id>
  </id_info>
  <brief_title>Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Myocardial Infarction (MI) Patient</brief_title>
  <official_title>Comparison the Therapeutic Outcomes of Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Patient With Acute Myocardial Infarction Underwent PCI Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although a percutaneous coronary intervention (PCI) can be used to open up the blocked artery
      and restore blood flow to the heart muscle after myocardial infarction, there may be a
      significant amount of heart tissue that has been irreversibly damaged. Recent studies have
      shown that adult stem cells from bone marrow may be able to improve heart function and
      prevent from heart remodeling due to heart failure.

      This study will evaluate the safety and effectiveness of using adult bone marrow derived stem
      cells for improving heart function in MI patients with Left Anterior Descending (LAD)
      involvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient from both gender, who had acute MI within recent 3 Weeks in LAD territory and would
      underwent PCI are eligible for this study. The bone marrow derived AC 133+ and MNC would be
      intracoronary injected to the patients during PCI procedure. The control group would be
      received just serum during PCI. The patient would be followed every month and at the end of
      6th and 18thmonth the case and control groups will be evaluated by stress echo and Tc99 scan.

      The totality of evidence from trials investigating autologous whole bone marrow infusion into
      patients following myocardial infarction supports the safety of this approach in terms of
      efficacy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase from baseline in ejection fraction</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease LVESV/LVEDV/LVM index</measure>
    <time_frame>6 months</time_frame>
    <description>left ventricular end systolic volume (LVESV) left ventricular end diastolic volume (LVEDV) Left Ventricular mass (LVM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease the number of Non Viable segments from baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>AC133 recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra coronary injection of bone marrow derived AC133+ cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MNC recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra coronary injection of bone marrow derived MNC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection of autologous serum</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AC133</intervention_name>
    <description>intra coronary injection of bone marrow derived AC133+ cells</description>
    <arm_group_label>AC133 recipients</arm_group_label>
    <other_name>AC133 injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MNC</intervention_name>
    <description>intra coronary injection of bone marrow derived MNC</description>
    <arm_group_label>MNC recipients</arm_group_label>
    <other_name>MNC injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CONTROL</intervention_name>
    <description>autologous serum injection</description>
    <arm_group_label>control</arm_group_label>
    <other_name>placebo injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI&gt; 30

          -  First acute MI in LAD territory

          -  St elevation MI

          -  Ejection fraction: 20-45%

          -  at least two non - mobile or less mobile segment of left ventricular myocard.

          -  Successful PCI with stenting

        Exclusion Criteria:

          -  Multivessel ceremony artery disease

          -  Pulmonary edema

          -  SBP &lt; 80 mmHg

          -  Thrombocytopenia (PLT &lt; 50, 000)

          -  INR &gt; 2

          -  Hepatic failure or dysfunction

          -  Renal failure or dysfunction

          -  Positive HIV Ab/ HBC Ab/ HCV Ab/ HSV Ag

          -  Documental terminal illness

          -  Documental Malignancy

          -  Patient with sever coronary disease and unstability of vital sign

          -  History of leukopenia, Anemia, hepatic or renal dysfunction or malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masoud Ghassemi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, PhD,MD</last_name>
    <role>Study Director</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Davood Kazemi saleh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hossein Baharvand, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royan institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2010</study_first_posted>
  <last_update_submitted>December 25, 2012</last_update_submitted>
  <last_update_submitted_qc>December 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>bone marrow stem cell</keyword>
  <keyword>AC133</keyword>
  <keyword>mono nuclear cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

